Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
T. Rowe Price Associates, Inc. reported beneficial ownership of 2,951,116 shares of Tenax Therapeutics common stock, representing 17.2% of the class. The filing names CUSIP 88032L605 and states sole voting and dispositive power over the 2,951,116 shares. The T. Rowe Price Health Sciences Fund is disclosed with an interest in 2,543,505 shares (14.8%). The filing clarifies that Price Associates disclaims beneficial ownership and holds the securities as investment adviser for clients.
Insights
Large passive position disclosed; filing shows institutional concentration in Tenax.
The Schedule 13G/A reports 2,951,116 shares (17.2%) held with sole voting and dispositive power by T. Rowe Price Associates, Inc. This indicates significant institutional exposure that could influence shareholder voting outcomes if aggregated with other holders.
Ownership is reported as adviser-held; the filing explicitly states Price Associates disclaims beneficial ownership and that the holdings are managed for clients, including the T. Rowe Price Health Sciences Fund with 2,543,505 shares (14.8%). Subsequent filings would show any material changes in position.
Key Figures
Beneficially owned shares:2,951,116 sharesPercent of class:17.2%Health Sciences Fund interest:2,543,505 shares+2 more
5 metrics
Beneficially owned shares2,951,116 sharesAmount beneficially owned by T. Rowe Price Associates, Inc.
Percent of class17.2%Percent of Tenax common stock represented by 2,951,116 shares
Health Sciences Fund interest2,543,505 sharesT. Rowe Price Health Sciences Fund interest in Tenax common stock
Health Sciences Fund percent14.8%Percent of class represented by 2,543,505 shares held by the fund
CUSIP88032L605CUSIP for Tenax Therapeutics common stock listed on the filing
Key Terms
Schedule 13G/A, beneficially owned, sole dispositive power, disclaims beneficial ownership
4 terms
Schedule 13G/Aregulatory
"Amendment No. 1 ) TENAX THERAPEUTICS INC COMMON STOCK"
A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
sole dispositive powerregulatory
" (iii) Sole power to dispose or to direct the disposition of: 2951116"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
disclaims beneficial ownershipregulatory
"Price Associates ... declares and affirms that the filing ... is expressly denied"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many Tenax Therapeutics (TENX) shares does T. Rowe Price own?
T. Rowe Price reports beneficial ownership of 2,951,116 shares of Tenax common stock. The filing states this represents 17.2% of the class and that T. Rowe Price holds sole voting and dispositive power over these shares.
What stake does T. Rowe Price Health Sciences Fund hold in TENX?
The T. Rowe Price Health Sciences Fund holds 2,543,505 shares of Tenax common stock, representing 14.8% of the class. The filing lists this interest as part of the adviser-managed portfolio cited in the Schedule 13G/A.
Does T. Rowe Price claim beneficial ownership of TENX shares?
No. T. Rowe Price explicitly disclaims beneficial ownership and states it acts as investment adviser for clients. The filing clarifies that ultimate power to receive dividends or sale proceeds rests with the underlying clients.
What voting and dispositive powers are reported on the filing?
The filing reports sole voting power of 2,951,116 shares and sole dispositive power of 2,951,116 shares, with 0 shared voting or dispositive power listed in the Schedule 13G/A.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
TENAX THERAPEUTICS INC
(Name of Issuer)
COMMON STOCK
(Title of Class of Securities)
88032L605
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
88032L605
1
Names of Reporting Persons
T. Rowe Price Associates, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
MARYLAND
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
2,951,116.00
6
Shared Voting Power
0.00
7
Sole Dispositive Power
2,951,116.00
8
Shared Dispositive Power
0.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
2,951,116.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
17.2 %
12
Type of Reporting Person (See Instructions)
IA
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
TENAX THERAPEUTICS INC
(b)
Address of issuer's principal executive offices:
101 GLEN LENNOX DRIVE, SUITE 300, CHAPEL HILL, NC, 27517
Item 2.
(a)
Name of person filing:
T. Rowe Price Associates, Inc.
(b)
Address or principal business office or, if none, residence:
1307 Point Street, Baltimore, MD 21231
(c)
Citizenship:
Maryland
(d)
Title of class of securities:
COMMON STOCK
(e)
CUSIP No.:
88032L605
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
2951116
(b)
Percent of class:
17.2 %
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
2951116
(ii) Shared power to vote or to direct the vote:
0
(iii) Sole power to dispose or to direct the disposition of:
2951116
(iv) Shared power to dispose or to direct the disposition of:
0
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) [T. ROWE PRICE HEALTH SCIENCES FUND ]: T. ROWE PRICE HEALTH SCIENCES FUND, of which T. Rowe Price Associates, Inc. is the investment adviser, holds the securities reported herein in their investment portfolio managed by T. Rowe Price Associates, Inc. and such funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that they hold. T. ROWE PRICE HEALTH SCIENCES FUND has an interest in 2,543,505 of the class reported herein representing 14.8% of the class.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
